Insulin aspart: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 4:
| image = Insulin Aspart Structural Formula.gif
| alt = <!-- Clinical data -->
| tradename = NovoLog, NovoRapid, Fiasp,
| Drugs.com = {{drugs.com|monograph|insulin_aspart}}
| MedlinePlus = a605013
Baris 11:
| pregnancy_AU_comment = <ref name=Preg2019 /><ref name="Truvelog APMDS" /><ref name="Insulin aspart APAR">{{cite web |url=https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-200301.pdf |title=Australian Public Assessment Report for Insulin aspart |date=March 2021 |publisher=[[Therapeutic Goods Administration]] (TGA) |archive-url=https://web.archive.org/web/20210624194925/https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-200301.pdf |archive-date=24 June 2021}}</ref><ref>{{cite web |url=https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-rys-200827.pdf |title=Australian Public Assessment Report for Insulin aspart (rys) |publisher=[[Therapeutic Goods Administration]] (TGA) |date=August 2021 |archive-url=https://web.archive.org/web/20220205044655/https://www.tga.gov.au/sites/default/files/auspar-insulin-aspart-rys-200827.pdf |archive-date=5 February 2022}}</ref>
| pregnancy_category =
| routes_of_administration =
| ATC_prefix = A10
| ATC_suffix = AB05
| |||